Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Abstract Background There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This study focused on the efficacy, toxicity and the optimal chemotherapy regim...

Full description

Bibliographic Details
Main Authors: Nan Bi, Lipin Liu, Jun Liang, Shixiu Wu, Ming Chen, Changxing Lv, Lujun Zhao, Anhui Shi, Wei Jiang, Yaping Xu, Zongmei Zhou, Jingbo Wang, Wenqing Wang, Dongfu Chen, Zhouguang Hui, Jima Lv, Hongxing Zhang, Qinfu Feng, Zefen Xiao, Xin Wang, Tao Zhang, Weibo Yin, Junling Li, Jie He, Luhua Wang
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
Locally advanced
Non-small-cell lung cancer
ECOG 2
Chemoradiotherapy
Efficacy
Toxicity
Online Access:http://link.springer.com/article/10.1186/s12885-020-06780-x

Internet

http://link.springer.com/article/10.1186/s12885-020-06780-x

Similar Items